Share This! Tweet This! Recommend Us! Print Page

Neurology

Find a Doctor
Find a Location

The MultiCare Neuroscience Center of Washington has been active in the search for new and innovative treatments for many of the devastating neurologic diseases that affect our community. The MultiCare Research Institute has partnered with the MultiCare Neuroscience Center of Washington to provide research opportunities to our community in many areas of neurologic science including:

Multiple Sclerosis

John Huddlestone, MD and the site are nationally recognized for excellence. He has been involved in clinical trials for more then 2 decades. Trials are conducted at South Sound’s only nationally recognized Multiple Sclerosis Center. The site has participated in trials evaluating

  • First oral medications for treatment of MS
  • Monoclonal antibody therapy in MS
  • Novel therapeutics with specific targets in MS
  • Comparison of Disease Modifying Therapies in MS
  • Long-term follow-up trials after Exposure to Investigational Products

Post-Herpetic Neuralgia pain control

Restless Leg Syndrome control of symptoms

Migraine Headache treatment and suppression

Movement Disorders treatment

Epilepsy

Two Board Certified Epileptologists, Laura Hershkowitz, DO and Laura Lynam, MD offer clinical trials to patients with epilepsy.


The Investigators in Neuroscience medicine include:

Laura Hershkowitz, DO, FACN (Principal Investigator)

John Huddlestone, MD, FAAN (Principal Investigator)

Peter Kwon, MD

Laura Lynam, MD,

Traci Ryan, MD

Yu Zhu, MD, PhD

Neurology Studies Accepting Participants

Multiple Sclerosis - Relapse (Ages 18-55)
Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Purpose: This study is seeking patients who have clinically diagnosed Multiple Sclerosis with at least 2 documented clinical attacks (relapses) within the last 2 years. This study is comparing Ocrelizumab to Rebif.

Who Can Participate?
Patients who meet the relapse criteria listed above. Medication restrictions may apply depending of what type of MS modifying therapy you are currently using.

Diagnosis or Condition
: Patients with a clinical diagnosis of Multiple Sclerosis

Medication
: Investigational Product is delivered via IV infusion every 6 months.  

Age
: Between 18 and 55 years of age

Sex
: Males and Females

Visits
:   Patients will be followed for up to 96 weeks and includes 4 infusion treatment cycles every 6 months

Stipend
: You will be compensated for your time and travel

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator
:   Andrea Thompson, 253-403-7440
Neuropathic Pain
Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis

Purpose: This study is seeking patients who have clinically diagnosed MS-related central neuropathic pain, but are otherwise in generally good health.

Who Can Participate?
Patients who have been diagnosed with MS-related central neuropathic pain for at least 90 days prior to study participation. Patient may be on any or no MS modifying therapy.

Diagnosis or Condition
: Patients with a clinical diagnosis of Multiple Sclerosis

Medication
: Investigational Product is delivered via oral capsule twice daily.

Age
: Between 18 and 85 years of age

Sex
: Males and Females

Visits
:  Seven visits over a period of 13 weeks

Stipend
: You will be compensated for your time and travel

Principal Investigator(s)
John Huddlestone, MD, FAAN

Study Coordinator
:   Andrea Thompson, 253-403-7440